This interview analysis is sponsored by Deloitte and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.
Problems in different industries can look quite similar when looked at from the perspective of data. Though diverse business problems originate from distinct domains and needs, they often share a common thread and solution.
Takeda Pharmaceuticals is a 240-year-old, leading biopharmaceutical company headquartered in Tokyo, Japan, with a global hub in Cambridge, Massachusetts. The company has a global presence, operating in more than 80 countries across North America, Europe and Asia.
Lily is a pharmaceutical giant with a legacy dating back to its founding in 1876 by Colonel Eli Lilly. The company engages more than 9600 employees in research and development, with clinical research conducted in more than 55 countries. As of 2022, the company clocked a revenue of $28,541.4 million and made a net income of $6,244.8 million.
AI has profound implications for drug discovery, ushering in a new era of innovation and efficiency. Recent milestones - such as the first AI-designed drug molecule to enter human clinical trials and the prediction of protein structures for millions of proteins - showcase the transformative power of AI in this domain.
